ReForm Biologics Announces the Appointment of Alan Herman, Ph.D. and Fred Larimore, Ph.D. to Scientific Advisory Board

WOBURN, Mass.--(BUSINESS WIRE)-- ReForm Biologics, a pharmaceutical technology company developing innovative biologic formulations to improve drug delivery and manufacturing, today announced the appointment of Alan Herman, Ph.D. and Fred Larimore, Ph.D. to the company’s Scientific Advisory Board (SAB).

“Fred Larimore and Alan Herman together bring decades of experience in the development and commercialization of biologics and biosimilars to ReForm’s Scientific Advisory Board,” said John M. Sorvillo, PhD, Chief Executive Officer, ReForm Biologics. “As Chief Scientific Officer at Coherus Biosciences, Alan was leader in the company’s drive to create a new model for developing safe, high-quality biosimilar therapeutics. Fred’s experience in advising leading companies in process development, commercialization, and manufacturing of biotech products will be invaluable as ReForm expands our agreements with major pharmaceutical and biotech companies to improve biologic formulations. On behalf of all of us at ReForm, I welcome Alan and Fred to the SAB.”

“ReForm is using its unique technology and scientific expertise to improve the formulation of biologics, which can lead to better efficiency in manufacturing, improved product stability or alternative dosing,” said Alan Herman. “I look forward to working with my fellow SAB members as we help the ReForm team make biologics better.”

“ReForm has agreements with leading drug developers including Bayer AG, Astellas and KBI Pharmaceuticals to improve the characteristics of biologics for the ultimate benefit of patients,” said Fred Larimore. “I am excited to be joining the ReForm Scientific Advisory Board to help them achieve this important goal.”

Alan Herman is Principal at Alan Herman Consulting. He has over 35 years of experience in the life sciences sector, most recently as Chief Scientific Officer at Coherus Biosciences. Previously, he was VP of Product Development and CSO at Althea Technologies and President of WindRose Analytica, Inc. He has a Ph.D. in Protein Chemistry from Duke University.

Fred Larimore is Principal Consultant at Sierra Vista (SV) Biotech Consulting with over 30 years experience in biotech development, manufacturing, and technology transfer. Previously, he was VP of Development at Cook Pharmica and a Research Fellow at Eli Lily & Co. He obtained his Ph.D. in Biochemistry from the University of Minnesota – Twin Cities.

About ReForm Biologics

ReForm Biologics has developed a technology platform that transforms the formulation of biotherapeutics for the ultimate benefit of patients. Our patented technology can extend product life-cycles, enable alternative dosing, and improve manufacturing efficiency for our biopharmaceutical partners. With multiple industry alliances to date, we offer formulation development collaborations and product-specific licenses for a broad spectrum of protein-based therapeutics.

We don’t make biologics — we make biologics better. www.reformbiologics.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20190529005056/en/